Jazz Pharmaceuticals appoints vice president of r&d

Jeffrey Tobias also takes chief medical officer role

Jazz Pharmaceuticals, a US developer of pharmaceuticals for neurology and psychiatry based in Palo Alto, California, has appointed Jeffrey Tobias, as senior vice president of research and development and chief medical officer. He takes up his new roles on 17 October.

Tobias has 20 years of experience in the biopharmaceutical industry across all phases of drug development, including regulatory filings in the US and Europe.

He has broad experience with a variety of therapeutic products spanning numerous clinical areas, including pain and neurological disorders.

Most recently, he was executive vice president of research and development at NeurogesX, where he has also been chief medical officer since 2005.

Prior to this Tobias was managing director of an independent biopharmaceutical consulting firm from 1996 to 2006, where he supported clients in all aspects of clinical development, technology assessment and strategic planning. He has also served in various roles in drug discovery and clinical development at ALZA, Chiron and XOMA.

Tobias also has 10 years of experience in clinical and academic medicine, focusing on internal and pulmonary and critical care medicine.

You may also like

Pharmaceutical

Jazz Pharmaceuticals commercialises enhanced antibody, Ziihera, for biliary tract cancer

The therapeutic antibody was developed using ProBioGen's GlyMaxX technology, creating an afucosylated product with more ADCC-mediated cell killing activity
Design & Build

Jazz Pharmaceuticals among ISPE FOYA winners

Ardmac supplied and installed the cleanroom in the biopharmaceutical company's winning facility in Ireland
Finance

Jazz concludes merger with Azur Pharma

Forms a specialist in CNS and women’s health products
Regulatory

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical

Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026

Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory

FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths

The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Manufacturing

Bio-Sourcing and Tiny Cargo collaborate to develop oral monoclonal antibody therapies

Bio-Sourcing and Tiny Cargo Company have announced a strategic alliance to co-develop oral monoclonal antibody therapies using goat milk extracellular vesicles
Subscribe now